Zobrazeno 1 - 10 of 115 pro vyhledávání: '"Nancy Leung"'
3
Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis
Autor: Bingyi Yang, Xiaotong Huang, Huizhi Gao, Nancy Leung, Tim Tsang, Benjamin Cowling
Background: Dose fractionation of Coronavirus Disease 2019 (COVID-19) vaccine could effectively accelerate global vaccine coverage, while supporting evidence of efficacy, immunogenicity, and safety are unavailable, especially with emerging variants.M
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ae6c9de65c46675a47300df767994f7
https://doi.org/10.21203/rs.3.rs-1571821/v1
Zobrazit plný text záznamu
7
Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B
Autor: Tokutei M. K. So, George K. K. Lau, Stefan Zeuzem, Nancy Leung, Aldo Trylesinski, Yu Dong, Henry Lik-Yuen Chan, Eva Herrmann, Nikolai V. Naoumov
Publikováno v: Infectious Diseases and Therapy
Introduction Viral kinetics has proved useful in understanding antiviral potency, determining antiviral profiles and optimizing treatment strategy. Methods This was a randomized, open-label study comparing the viral kinetics in 46 hepatitis B e antig
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c3e2552516e1269a52b8aa5b64ca502
https://doi.org/10.1007/s40121-014-0039-5
Zobrazit plný text záznamu
8
Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B
Autor: Yun-Fan Liaw, Claudio Avila, Satawat Thongsawat, Yuming Wang, Patricia Lopez, Mobin Wan, J L Hou, Nancy Leung, You C. Chao, Jidong Jia, Junqi Niu, Chao Wei Hsu, Didier Samuel, Young Myoung Moon, W. Bao, Edward Gane
Publikováno v: Liver International. 31:676-684
Background: In the GLOBE trial, telbivudine demonstrated superior efficacy to lamivudine at 2 years in patients with chronic hepatitis B (CHB). Aims: To investigate the long-term efficacy and safety of telbivudine in the telbivudine-treated cohort fr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5a33bdd012c1ea7ca3b8c866efd12f8e
https://doi.org/10.1111/j.1478-3231.2011.02490.x
Zobrazit plný text záznamu
9
Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance
Autor: Bernard Willems, Hie-Won Hann, Lynn D. Condreay, Nancy Leung, Stephen D. Gardner, Mary Woessner, Eugene R. Schiff, David Mutimer, William M. Lee, Carol L. Brosgart, Susan Dixon, Robert P. Perrillo
Publikováno v: Hepatology International. 5:654-663
We and others have reported that adding adefovir dipivoxil (adefovir) to lamivudine results in virological and biochemical improvement in cases of lamivudine resistance. The current study assessed the efficacy and safety of combined therapy after 104
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52ee96b0a48865a5b50aacc4b5c2fd91
https://doi.org/10.1007/s12072-010-9228-9
Zobrazit plný text záznamu
10
Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues
Autor: Nancy Leung
Publikováno v: Liver International. 31:85-89
HBeAg seropositivity is a marker for active viral replication. In the natural history of chronic hepatitis B infection, HBeAg marks the first two of the four phases, namely the immune tolerant phase and the immune clearance phase, and is associated w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25a96538089a068d97da961ccaab8577
https://doi.org/10.1111/j.1478-3231.2010.02387.x
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje